NEW YORK (GenomeWeb) – Protea Biosciences today announced that it has entered into an agreement to buy the research services firm VivoPharm for cash and equity.

According to the firm's 8-K filed with the SEC on April 6, Protea will acquire all shares of Hershey, Pa.-based VivoPharm and its subsidiaries for $11.2 million, including $5.4 million in cash and $5.7 million in the form of 570,053 shares of new Series A stock. Upon completion of the deal, VivoPharm will operate as a business unit of Protea, the firm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.